Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
Yang Yang, Master of medicine 1,2 ; Fupin Hu, PhD 1 ; Demei Zhu, Bachelor 1 ; 1 Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China (People's Republic), 2 Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China (People's Republic) Session: 68. Novel Antimicrobials and Approaches Against Resistant Bugs Thursday, October 3, 2019: 12:15 PM Background. Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-positive (GP) and anaerobic isolates from Phase 3 ABSSSI clinical trials were determined.
Methods. 313 isolates were collected from 65 participated sites and sent to a central laboratory for MIC testing. Clinical isolates included 34 anaerobes (15 Finegoldia magna, 8 Actinomyces spp., 4 Prevotella spp., 3 Propionibacterium avidum, 2 Peptostreptococcus spp., 1 Veillonella spp. and 1 Bacteroides fragilis), 187 S. aureus (59. 7%). 12 S. pyogenes, 5 Enterococcus and 75 other Gram-positive organisms. Broth micro-dilution method was used to determine the MIC of contezolid, linezolid and other comparators to facultative isolates. Agar dilution was carried out for the anaerobes.
Results. For both 33 MRSA and 154 MSSA MIC 50/90 values of contezolid and linezolid were 2 mg/L. One E. faecalis showed decreased susceptibility to oxazolidinones (both MIC = 4). 1 mg/L contezolid and linezolid could inhibit 12 S. pyogenes. 2 mg/L contezolid and linezolid could inhibit 15 Finegoldia magna. 0.5 mg/L contezolid and linezolid could inhibit 8 Actinomyces spp. To one Bacteroides fragili, two Prevotella bivia and one Leuconostoc lactis (Intrinsic resistant to vancomycin) the MIC of contezolid were 4 or 8 mg/L. In general, Contezolid had lower or equal MIC 50/90 values against both GP and ANA species compared with linezolid for all organisms.
Conclusion. Contezolid demonstrated potent in vitro antibacterial activity against Gram-positive and anaerobic isolates tested. These data suggest that contezolid might be a beneficial supplement to the arena against MDR Gram-positive infection.
Disclosures. All authors: No reported disclosures. Background. Multidrug-resistant Gram-negative bacilli (MDRGNB) are emerging as a challenging cause of hospital-acquired infections and represent a critical need for innovative antibacterial development. New oxopyrazole agents targeting penicillin-binding proteins (PBPs) based on a non-β-lactam core and incorporating a siderophore moiety (Figure 1) which facilitates transport to the periplasm are being developed that show promise against Gram-negative organisms including multidrug-resistant strains of E. coli, K. pneumoniae and P. aeruginosa.
In vitro Activity of a New Generation Oxopyrazole Antibiotic Against
Methods. YU253434, an example of this new class of antibacterials, was investigated in vitro. Minimum inhibitory concentrations (MICs) were determined by broth microdilution against a representative panel comprising 15 strains each of E. coli, K. pneumoniae and P. aeruginosa, which contain extended-spectrum β-lactamase (ESBL) and/or carbapenemases genes.All studies were performed according to current Clinical & Laboratory Standards Institute (CLSI) guidelines using iron-depleted media. Ceftazidime breakpoints were arbitrability chosen as a reference for YU253434 (susceptibilities ≤4 μg/mL for Enterobacteriaceae and ≤8 μg/mL for P. aeruginosa).
Results. MIC testing (Figures 2-4 ) against E. coli showed 11 strains were YU253434 susceptible (compared with 6 for ceftazidime, and 3 for imipenem); against K. pneumoniae 13 strains were YU253434 susceptible (compared with 2 for ceftazidime and 6 for imipenem); against P. aeruginosa 10 strains were YU253434 susceptible (compared with 0 for both ceftazidime and imipenem). There appeared to be no correlation between YU253434 resistance and the presence of specific lactamase genes.
Conclusion. YU253434, a new generation oxopyrazole antibiotic, demonstrated promising in vitro potency against a panel of E. coli, K. pneumonia, and P. aeruginosa strains which contain ESBL and/or carbapenemases genes.
